News & Events

Upcoming Events

No upcoming event attendances scheduled.

Press Releases

Bilthoven, July 20, 2023

Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors

Sapreme announced today the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors. Both bring a wealth of executive, business and clinical development expertise from large pharmaceutical and innovative biotech companies as Sapreme now builds upon preclinical proof of concept in several disease indications and delivery models. Read the full press release here.


October 7, 2021

Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the round follows promising 2020 and 2021 preclinical data demonstrating the effectiveness of Sapreme’s endosomal escape compound, SPT001. Read the full release here.

About Sapreme:

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contacts: Guy Hermans, CEO   |  +31 30 760 09 76   |

For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher  |  +49 89 238 877 30  |